| Literature DB >> 33520649 |
Jose Enrique Montoya1, Lorraine Marie Item2, Shaira Ann Ganggay3, Katrin Jovellanos3, Jonah Marie Punzalan3, Glory Baltazar4.
Abstract
The advent of the COVID-19 pandemic has stretched most healthcare systems to the point that if no adaptations are made, failure will most likely happen. The Philippine healthcare system, with its meager resources, is very much vulnerable to this. During the start of the pandemic, Bataan General Hospital and Medical Center has been converted to a COVID-19 hub, leaving cancer care and treatment displaced. We describe our experience in the feasibility of using a religious facility as an interim place for continuing oncology treatment. An outpatient chemotherapy unit was set up using the main hall of the Residencia Sacerdotal, a religious facility, in Bataan. General practices for infection control, workflow and service delivery were in accordance with existing guidelines. A total of 56 adult patients and 22 pediatric patients were seen for chemotherapy during the period of April 28 to July 15, 2020. A total of 144 chemotherapy sessions for adults and 190 sessions for pediatric patients were done. Fifty nine patients (43 adults and 16 pediatric) were tested for COVID-19 RT PCR (GeneXpert®), as baseline prior to chemotherapy, and all were negative. During the course of treatment, adverse events were noted including infusion reactions, hematologic complications which resolved without any complications. No nosocomial infection was recorded both for patients and healthcare workers. To conclude, in the COVID-19 Pandemic Era adapting to the situation is the best way forward. In our setting, continuing cancer care in a religious facility is a feasible alternative.Entities:
Keywords: Bataan; COVID-19; Cancer care; Chemotherapy; Pandemic; Philippines; Religious facility
Year: 2020 PMID: 33520649 PMCID: PMC7836373 DOI: 10.1016/j.jcpo.2020.100269
Source DB: PubMed Journal: J Cancer Policy ISSN: 2213-5383
Clinical profile of adult oncology patients during the period (N = 56).
| Variable | Results |
|---|---|
| Age (in years) | Mean ± SD = 54.93 ± 13.03 |
| Min = 26 | |
| Max = 76 | |
| Sex (# of patients) | Female = 45 (80.36 %) |
| Male = 11 (19.64 %) | |
| Diagnosis (# of patients) | Invasive Ductal Carcinoma = 33 (58.93 %) |
| Colon Adenocarcinoma = 7 (12.50 %) | |
| Rectal Adenocarcinoma = 5 (8.93 %) | |
| Nasopharyngeal Carcinoma = 4 (7.14 %) | |
| Cervical Carcinoma = 2 (3.57 %) | |
| Hodgkin Lymphoma = 2 (3.57 %) | |
| Angiosarcoma = 1 (1.79 %) | |
| Gastric Adenocarcinoma = 1 (1.79 %) | |
| Thymic Carcinoma = 1 (1.79 %) | |
| Cancer Patient Prioritization (ESMO Tiered Approach) (N = 56) | High = 39 (70 %) |
| Medium = 17 (30 %) | |
| Total number of chemotherapy sessions during the period (N = 144) by type for the same set of patients (N = 56) | Weekly paclitaxel = 45 (31.25 %) |
| Capecitabine = 22 (15.28 %) | |
| CapeOx = 16 (11.11 %) | |
| AC = 14 (9.72 %) | |
| Docetaxel = 13 (9.03 %) | |
| Gemcitabine Carboplatin = 11 (7.64 %) | |
| Paclitaxel Carboplatin = 10 (6.94 %) | |
| ABVD = 6 (4.17 %) | |
| Tamoxifen = 3 (2.08 %) | |
| GemOX = 2 (1.39 %) | |
| Trastuzumab = 2 (1.39 %) |
Adverse Events – Adults (6 out of 144 sessions = 4.17 %).
| Adverse Events | Grade (according to CTCAE ver 5) | N = 6 sessions |
|---|---|---|
| Anemia | 1 | 1 |
| Transaminitis | 2 | 1 |
| Nausea/Vomiting | 1 | 2 |
| Infusion Reaction | 2 | 2 |
Clinical Profile of Pediatric Oncology patients during the period (N = 22).
| Variable | Results |
|---|---|
| Age (in years) | Mean ± SD = 6.77 ± 3.59 |
| Min = 1 | |
| Max = 15 | |
| Sex (# of patients) | Girls = 8 (36.4 %) |
| Boys = 14 (63.6 %) | |
| Diagnosis (# of patients) | Acute Lymphoblastic Leukemia = 19 (86.5 %) |
| Acute Myeloid Leukemia = 1 (4.5 %) | |
| Juvenile Myelomonocytic Leukemia = 1 (4.5 %) | |
| Hodgkin Lymphoma = 1 (4.5 %) | |
| Total number of chemotherapy sessions during the period (N = 190) by type for the same set of patients (N = 22) | L-asparaginase = 69 (36.3 %) |
| Cytarabine = 30 (15.8 %) | |
| Vincristine = 30 (15.8 %) | |
| Intrathecal cytarabine, hydrocortisone and methotrexate plus IV Vincristine = 17 (8.9 %) | |
| Doxorubicin and Vincristine = 15 (7.9 %) | |
| Methothrexate and Vincristine = 13 (6.8 %) | |
| Intrathecal cytarabine, hydrocortisone and methotrexate plus Cytarabine = 10 (5.2 %) | |
| Cyclophosphamide = 6 (3.2 %) | |
| Total Procedures Done | Bone Marrow Aspiration = 5 |
| Intrathecal = 27 |
Adverse Events – Children (5 out of 190 sessions = 2.63 %).
| Adverse Events | Grade (according to CTCAE ver 5) | N = 5 sessions |
|---|---|---|
| Anemia | 3 | 2 |
| Thrombocytopenia | 3 | 1 |
| Neutropenia | 3 | 2 |